Atorvastatin reduced soluble receptors of tnf-alpha in systemic lupus erythematosus

Atorvastatin reduced soluble receptors of tnf-alpha in systemic lupus erythematosus

Author Ferreira, G. A. Google Scholar
Teixeira, A. L. Google Scholar
Calderaro, D. C. Google Scholar
Sato, E. I. Autor UNIFESP Google Scholar
Abstract Objective The aim of this study was to evaluate the efficacy of atorvastatin to reduce the plasma levels of TNF system molecules (TNF-alpha, sTNFR1 and sTNFR2) and to assess their association with risk factors for accelerate atherosclerosis and clinical disease activity scores in SLE patients. Methods In a previous study, 64 female SLE patients received 20 mg/day of atorvastatin and 24 SLE patients (non-treated group) were followed for 8 weeks. Plasma levels of TNF-alpha, sTNFR 1 and sTNFR 2 were measured by ELISA, at baseline and at the end of the study. Results The plasma levels of sTNFR1 and sTNFR 2 showed a positive correlation with SLEDAI score. We also found a positive correlation between TNF-alpha and sTNFR 1 levels and SLICC score. Patients with current nephritis and patients with anti-dsDNA antibodies presented higher sTNFR1 and sTNFR2 levels. Patients with abdominal obesity and arterial hypertension also had higher plasma levels of soluble receptors. At the end of 8 weeks, we observed a significant decrease in sTNFR1 plasma levels in patients receiving atorvastatin [median (percentile), 876.5 (717-1284 pg/ml) vs. 748 (629.6-917.3 pg/ml), p=0.03], without difference regarding TNF-alpha and sTNFR2 plasma levels. The SLEDAI and SLICC scores were independent determinants of the plasma levels of sRTNF1. Conclusion Atorvastatin reduced soluble receptors of TNF-alpha. The plasma levels of TNF-alpha, sTNFR1 and sTNFR2 may play a role in SLE activity and atherosclerosis, and might be evaluated as targets for new therapies.
Keywords Systemic Lupus Erythematosus
Atherosclerosis
Receptors
Tumour Necrosis Factor
AtorvastatinTumor-Necrosis-Factor
Disease-Activity
Proinflammatory Cytokines
Insulin-Resistance
Therapy
Risk
Expression
Statins
Markers
Sle
Language English
Sponsor CNPq
Fapemig
Date 2016
Published in Clinical And Experimental Rheumatology. Pisa, v. 34, n. 1, p. 42-48, 2016.
ISSN 0392-856X (Sherpa/Romeo, impact factor)
Publisher Clinical & exper rheumatology
Extent 42-48
Origin http://www.clinexprheumatol.org/abstract.asp?a=9060
Access rights Closed access
Type Article
Web of Science ID WOS:000371850400007
URI http://repositorio.unifesp.br/handle/11600/49591

Show full item record




File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account